Over the past decade, there has been an emergence of commercially available home devices to help monitor an infant’s vital signs during sleep. These devices aim to provide reassurance and peace of ...

Puzzler poll: Urticarial rash in a 9-hours-old male ...

After 9.5 months, 94% of participants reported an improvement in incontinence symptoms, with 58% experiencing complete resolution and 18 (36%) reporting greater than 50% reduction in the number of ...

The newly-approved indication is for children aged 4 years and older who weigh 33 < 66 lbs, expanding on the August 9, 2024 approval in children at least 66 lbs. As of March 5, 2025, epinephrine nasal ...

Mike Hennessy Jr, President and CEO of MJH Life Sciences kicks off our March Mental Health issue with a look into the ongoing pediatric mental health crisis. The pediatric mental health crisis in the ...

In this Q+A interview, Matthew Greenhawt, MD, breaks down a poster presentation from AAAAI / WAO joint congress meeting, highlighting increasing EoE incidence and prevalence. According to data from a ...

According to data presented at AAAAI, berotralstat demonstrated a well tolerated safety profile and early and sustained reductions in monthly HAE attacks among patients aged 2 to under 12 years.

Colleen Sloan, PA-C, RDN, emphasizes the importance of learning to spot added sugars, compare portion sizes, and recognize misleading marketing claims to give patients a practical tool to take ...

Panelists discuss offering guidance to parents and caregivers experiencing atopic dermatitis for the first time, emphasizing the importance of education on managing flare-ups, proper skin care ...

Panelists discuss the current treatment landscape for atopic dermatitis, noting significant advances in biologics and systemic therapies, and share optimism about the future of management, ...

On exam, the patient is found to have circular, slightly raised, blanching, erythematous papules on the lower extremities and abdomen. A 6-day-old male with history of waxing and waning urticarial ...

Results will be included an a final analysis of safety and efficacy data for CTx-1301, which will be included in a NDA submission with the FDA, stated Cingulate Inc. Cingulate Inc. (NASDAQ: CING) has ...